Illuminate has extensive experience in modelling the impact of generic medicine entry for medicolegal work. Illuminate has been involved in multiple patent infringement cases, where generic brands have entered the market before patent expiry or were incorrectly prohibited market entry. In each case, we have analysed the impact generic entry has on volume of units sold, market share, price discounting and the impact of price disclosure.
Using different types of regression analyses, the results and findings were used to support and shape arguments on the impact of generic entry. These modelling exercises have provided Illuminate significant insight into generic medicine launching strategies, as well as the ability to forecast sales with price disclosure.